Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Gastroenterology and hepatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Metabolic dysfunction-associated steatotic liver disease

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Uncomplicated steatosis is not an emergency. Jaundice, encephalopathy, ascites, gastrointestinal bleeding, sepsis or acute kidney injury suggests advanced decompensation or another acute insult and requires urgent hospital assessment under the cirrhosis pathway rather than routine MASLD follow-up.

Overview

Identify metabolic dysfunction-associated steatotic liver disease, stratify fibrosis rather than relying on enzymes, and reduce liver and cardiovascular risk through coordinated care.

MASLD encompasses simple steatosis and metabolically driven steatohepatitis with variable fibrosis. Insulin resistance, adipose inflammation and lipotoxicity contribute, but progression is heterogeneous; fibrosis stage predicts liver-related outcome more reliably than aminotransferase concentration.

The central decision is who has, or is likely to develop, advanced fibrosis. Incidental steatosis should trigger metabolic assessment and a structured non-invasive fibrosis pathway, not either dismissal as harmless fat or automatic specialist referral for everyone.

Terminology and pathways are evolving. UK services may still use legacy NAFLD labels in documents and coding; clinicians should recognise the equivalence while documenting alcohol exposure and other causes carefully enough to identify combined aetiology.

Key points

  • MASLD describes hepatic steatosis in a person with cardiometabolic risk after other major causes are assessed; metabolic and alcohol-related injury can coexist.
  • Type 2 diabetes, central adiposity, dyslipidaemia, hypertension, obstructive sleep apnoea and polycystic ovary syndrome increase risk, but lean people can also develop advanced disease.

Aetiology

01

Cardiometabolic dysfunction

Central adiposity, type 2 diabetes, dyslipidaemia, hypertension and insulin resistance strongly predispose to hepatic fat accumulation and progressive injury.

02

Genetic and lean susceptibility

Inherited variants, ethnicity, body-fat distribution and sarcopenia explain why advanced MASLD can occur without high body mass.

03

Overlapping liver insults

Alcohol, sleep apnoea, medicines and other liver diseases can coexist with metabolic steatosis and accelerate fibrosis rather than fitting exclusive labels.

Pathophysiology

  1. 1
    Insulin-resistant fat influx

    Adipose lipolysis and hepatic lipid synthesis deliver more fatty acid than hepatocytes can safely oxidise or export, producing steatosis.

  2. 2
    Lipotoxic inflammation

    Toxic lipid species, oxidative stress and immune activation injure hepatocytes, creating steatohepatitis in a susceptible subset.

  3. 3
    Fibrogenesis and architectural distortion

    Repeated injury activates stellate cells and collagen deposition, progressing from pericellular fibrosis to cirrhosis and portal hypertension.

Clinical features and red flags

Incidental steatosis

Ultrasound or CT may show a bright or low-attenuation liver in an asymptomatic person. This is an entry point for aetiology and fibrosis assessment, not a complete diagnosis.

Metabolic risk phenotype

Central adiposity, type 2 diabetes, hypertension, high triglycerides, low HDL, sleep apnoea or PCOS makes MASLD likely, though body mass index alone misses lean disease and ethnicity-related risk.

Possible advanced fibrosisRed flag

Thrombocytopenia, splenomegaly, low albumin, prolonged INR, palmar erythema or a high non-invasive fibrosis result suggests portal hypertension or cirrhosis even when ALT is normal.

Decompensated diseaseRed flag

Ascites, variceal bleeding, jaundice, encephalopathy or renal dysfunction indicates cirrhosis complications and needs urgent structured assessment, not a routine lifestyle-only appointment.

Competing or combined cause

Harmful alcohol exposure, viral risk, autoimmune features, iron overload, steatogenic medicines or rapid unexplained change requires parallel investigation because metabolic risk does not exclude another liver disease.

Paediatric or pregnancy context

Children and young people need age-specific thresholds and family-centred management; pregnancy changes metabolic risk and medicine choices and should use maternity and specialist pathways.

Investigations

  1. 01
    Metabolic and alcohol assessmentFirst step
    Why
    Establish cardiometabolic drivers and identify combined aetiology.
    Interpretation and limitations
    Measure body mass index and waist where appropriate, blood pressure, HbA1c or glucose and lipids; quantify alcohol in UK units without assuming metabolic risk makes alcohol history irrelevant.
  2. 02
    Liver blood tests and full blood count
    Why
    Identify another pattern and clues to portal hypertension or impaired synthesis.
    Interpretation and limitations
    ALT may be normal in advanced MASLD. Review AST, ALT, ALP, bilirubin, albumin, INR and platelets together; falling platelets or reduced synthesis matters more than isolated mild transaminitis.
  3. 03
    Liver aetiology screen
    Why
    Exclude viral, autoimmune, iron and other treatable liver disease.
    Interpretation and limitations
    Follow BSG guidance using hepatitis serology, immunoglobulins, autoantibodies and iron studies, with age- or context-specific tests. Ferritin may reflect metabolic inflammation rather than iron overload.
  4. 04
    Ultrasound liver
    Why
    Detect steatosis, focal lesions, biliary disease and signs of portal hypertension.
    Interpretation and limitations
    Routine ultrasound misses mild steatosis and cannot stage fibrosis reliably. Nodularity, splenomegaly or ascites is concerning, but a normal scan does not exclude advanced microscopic fibrosis.

Differential diagnosis

01

Alcohol-related liver disease

A neutral quantified alcohol history identifies overlapping harmful exposure; enzyme ratios and steatosis alone cannot reliably distinguish causation.

02

Viral or autoimmune liver disease

Serology, immunoglobulins and autoantibodies identify treatable alternatives that may coexist despite a strong metabolic phenotype at presentation.

03

Medicine-related steatosis

A compatible treatment timeline and known steatogenic exposure suggest drug contribution, interpreted alongside metabolic risk and other causes.

Management

01DetectionIncidental steatosis or abnormal ALTFirst stepImaging-detected fat, persistent transaminitis or high-risk metabolic disease.+
  1. 1Confirm metabolic risk, quantify alcohol and review medicines, viral exposure, family history and features of autoimmune or inherited disease; examine for chronic liver signs.
  2. 2Obtain a complete liver panel, blood count, metabolic measures and recommended aetiology screen rather than assuming every raised ALT in obesity is MASLD.
  3. 3First lineEnter the locally commissioned fibrosis pathway using ELF directly or a validated first-line score followed by ELF or elastography, documenting the specific cut-offs used.
  4. 4Refer advanced, discordant or unexplained results to hepatology; return low-risk disease to planned metabolic and fibrosis reassessment rather than discharging permanently.
02LifestyleStructured cardiometabolic treatment

Complications

01

Advanced fibrosis and decompensation

Progressive scarring causes portal hypertension, ascites, variceal bleeding and encephalopathy even when aminotransferases remain normal or mildly raised.

02

Hepatocellular carcinoma

Cancer risk rises substantially with cirrhosis and occasionally advanced pre-cirrhotic disease, linking accurate fibrosis staging to surveillance decisions.

03

Cardiovascular and metabolic disease

Myocardial infarction, stroke, diabetes progression and chronic kidney disease often dominate overall morbidity and require coordinated risk reduction.

Monitoring and follow-up

  • Track blood pressure, HbA1c, lipids, smoking, weight or agreed functional measures and sleep-apnoea treatment because cardiometabolic outcome is integral to liver care.
  • Repeat fibrosis assessment at the interval specified by NICE and the local pathway; do not substitute annual ALT for a validated fibrosis strategy.
  • When results disagree, review age, acute illness, platelet causes, elastography quality and alcohol exposure and seek hepatology advice instead of averaging incompatible scores.
  • In advanced fibrosis, maintain surveillance attendance, variceal assessment, renal and synthetic function, platelets, nutrition, sarcopenia and signs of decompensation.
  • For pharmacological weight or diabetes treatment, monitor product-specific adverse effects, renal function, glycaemia and nutrition, protecting against rapid loss of lean mass.

Special situations

Fibrosis drives prognosis

Steatosis quantity and ALT attract attention, but fibrosis stage is the strongest routine liver-related risk marker and should organise referral and surveillance.

Normal ALT can coexist with cirrhosis

Enzyme release measures current injury rather than scar burden. Platelets, synthesis, imaging and validated non-invasive fibrosis tests remain necessary in high-risk patients.

Cut-offs are pathway dependent

NICE and newer BSG-endorsed ELF material do not currently show the same threshold. Use one commissioned algorithm consistently and state it in the record.

Lean MASLD is real

Normal body mass index does not remove metabolic or genetic risk. Waist distribution, diabetes, lipids, ethnicity and sleep apnoea can reveal a high-risk phenotype.

Alcohol and metabolism combine

The newer name does not imply alcohol is irrelevant. Quantify exposure sensitively because combined injury may accelerate fibrosis and alter advice and coding.

Statins protect the main risk

Fear of mild stable transaminitis can lead to undertreatment of cardiovascular disease. Follow NICE monitoring rather than withholding indicated statin therapy reflexively.

Common pitfalls

  1. 01

    Reassuring a high-risk patient because ALT lies inside the reference interval.

  2. 02

    Using ultrasound brightness to stage fibrosis or treatment response.

  3. 03

    Applying NICE and BSG ELF cut-offs interchangeably within one pathway.

  4. 04

    Diagnosing MASLD without quantifying alcohol or excluding another liver disease.

  5. 05

    Withholding an indicated statin solely because stable steatosis is present.

  6. 06

    Prescribing vitamin E or pioglitazone broadly without specialist eligibility review.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA

Normal ALT in diabetes

A 59-year-old with type 2 diabetes, central adiposity and hypertension has ultrasound steatosis but ALT within the laboratory reference range. What is the most appropriate next principle?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Gastroenterology and hepatology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG49 MASLD recommendationsIdentification, ELF assessment, lifestyle and specialist treatment.
  • BSG endorsed ELF guidance2026-endorsed evidence supporting the updated ELF threshold.
  • BSG abnormal liver blood tests guidelineAetiology screen and fibrosis pathway principles.
  • NICE cardiovascular risk recommendationsLipid and cardiovascular risk management relevant to MASLD.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Normal ALT does not exclude steatohepatitis or advanced fibrosis, and the degree of ultrasound brightness does not stage scarring.
  • The key prognostic task is fibrosis assessment using the current commissioned pathway, not repeated routine liver panels alone.
  • As of August 2026, NICE NG49 and newer BSG-endorsed ELF guidance use different advanced-fibrosis cut-offs; apply the locally adopted threshold and do not mix algorithms.
  • FIB-4 can be a first step in some pathways but is unreliable in younger adults, acute illness and some older age groups; indeterminate or high results need a second-line test.
  • Lifestyle treatment should be specific and supported: sustained weight reduction, Mediterranean-style eating, reduced sugary drinks, regular aerobic and resistance activity, sleep and alcohol review.
  • Cardiovascular disease is a major cause of harm, so optimise blood pressure, lipids, glycaemia, smoking and obesity alongside liver care; statins are not routinely withheld because of stable MASLD.
  • Advanced fibrosis or cirrhosis triggers hepatology referral, portal-hypertension assessment and surveillance for hepatocellular carcinoma under the current cirrhosis pathway.
    • 05
    FIB-4 or local first-line scoreFirst line
    Why
    Provide inexpensive initial fibrosis triage in commissioned two-step pathways.
    Interpretation and limitations
    Calculate with contemporaneous stable values and apply age-aware local cut-offs. Acute illness, thrombocytopenia from another cause and extremes of age can misclassify risk; indeterminate or high results need second-line testing.
  • 06
    Enhanced Liver Fibrosis test
    Why
    Estimate advanced-fibrosis probability using direct serum markers.
    Interpretation and limitations
    Use the threshold commissioned locally. NICE NG49 historically specifies 10.51, while BSG-endorsed guidance supports 9.8; record which pathway was applied rather than switching cut-offs opportunistically.
  • 07
    Transient elastography
    Why
    Measure liver stiffness as a second-line fibrosis assessment.
    Interpretation and limitations
    Obesity, inflammation, cholestasis, congestion and recent food can affect quality or stiffness. Interpret reliability measures and local cut-offs; high results warrant hepatology assessment rather than declaring cirrhosis from one number.
  • 08
    Liver biopsy
    Why
    Resolve selected diagnostic uncertainty or stage disease when it will change specialist treatment.
    Interpretation and limitations
    Biopsy can distinguish steatohepatitis and grade fibrosis but has sampling and procedural risk. It is not required for routine primary-care diagnosis and should follow hepatology discussion.
    • MASLD without decompensation at any fibrosis stage.
    +
    1. 1Agree one or two measurable goals using the patient's culture, finances, disability, eating history and priorities; offer dietetic and weight-management support rather than generic instruction.
    2. 2Aim for sustainable weight reduction when appropriate through energy-aware Mediterranean-style eating, fewer sugar-sweetened drinks and both aerobic and resistance activity, increasing gradually from baseline.
    3. 3Treat diabetes, hypertension, dyslipidaemia, sleep apnoea and smoking using current NICE pathways; choose glucose-lowering or obesity medicines for their licensed indications and overall benefit.
    4. 4Reassess weight trajectory, waist or functional goals, HbA1c, lipids, blood pressure, alcohol and fibrosis risk, avoiding moral judgement when weight cycles or goals are not achieved.
    03AdvancedAdvanced fibrosis and cirrhosis careHigh non-invasive risk, imaging signs, low platelets or confirmed cirrhosis.+
    1. 1Refer to hepatology for confirmation, aetiology review and portal-hypertension assessment, including endoscopic or non-invasive variceal pathways as locally commissioned.
    2. 2Start hepatocellular carcinoma surveillance and cirrhosis vaccination, nutrition, bone-health and medicine-safety review according to current UK guidance.
    3. 3Educate about ascites, bleeding, jaundice, encephalopathy and infection warning signs and provide a clear route for urgent assessment if decompensation develops.
    4. 4Consider transplant referral after decompensation or adverse prognostic change and address cardiovascular fitness, frailty and weight through coordinated specialist support.
    04MedicineSpecialist pharmacological decisionsSteatohepatitis or advanced fibrosis where drug treatment is being considered.+
    1. 1Optimise medicines with proven indications for diabetes, obesity, lipids and blood pressure first, because reducing cardiovascular risk is a core outcome.
    2. 2Do not prescribe vitamin E, pioglitazone or a weight-loss agent solely for liver disease without applying the current NICE recommendation, licensing status and specialist assessment.
    3. 3Review adverse effects, reproductive plans, heart failure, fracture risk, renal function and interactions, and stop ineffective treatment according to the relevant pathway.
    4. 4Continue lifestyle, fibrosis and cardiometabolic monitoring because no medicine substitutes for surveillance or management of cirrhosis complications.
    Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
    Reduces cardiovascular events, a major source of morbidity and mortality in MASLD.

    Statin therapy

    Choose intensity and dose from the current NICE cardiovascular-risk and lipid pathway.

    Stable MASLD is not a routine contraindication. Obtain baseline liver tests and follow current stopping rules for unexplained marked enzyme rise, muscle symptoms, interactions or decompensated cirrhosis.

    Improves glycaemia and weight and may reduce metabolic drivers of steatotic liver disease.

    GLP-1 receptor agonist or dual incretin therapy

    Use only for an approved diabetes or weight-management indication and titrate by protocol.

    Do not present as universally licensed liver treatment. Review gastrointestinal effects, pancreatitis or gallbladder history, renal status, pregnancy plans and product-specific supply and eligibility guidance.

    May improve steatohepatitis in selected adults with advanced fibrosis, including some with diabetes.

    Pioglitazone

    Consider only through specialist advice under the current NICE MASLD recommendation.

    Weight gain, oedema, heart failure, fracture and bladder-cancer considerations require individual review. Confirm indication and monitoring; it is not routine therapy for simple steatosis.

    May improve liver histology in a restricted group with advanced fibrotic steatohepatitis.

    Vitamin E

    Consider only the specialist-selected formulation and course in eligible non-diabetic adults.

    Long-term high-dose safety and bleeding or prostate concerns require discussion. Do not use as an over-the-counter default, and reassess benefit through the specialist pathway.